Advagraf

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
30-10-2023
Summary of Product characteristics Summary of Product characteristics (SPC)
30-10-2023
Public Assessment Report Public Assessment Report (PAR)
31-03-2008

Active ingredient:

такролимус

Available from:

Astellas Pharma Europe BV

ATC code:

L04AD02

INN (International Name):

tacrolimus

Therapeutic group:

Имуносупресори

Therapeutic area:

Отхвърляне на присадката

Therapeutic indications:

Профилактика на отхвърляне на трансплантат при възрастни пациенти с бъбречни или чернодробни алографти. Лечение на отхвърляне на алографта, резистентно на лечение с други имуносупресивни лекарствени продукти при възрастни пациенти.

Product summary:

Revision: 26

Authorization status:

упълномощен

Authorization date:

2007-04-23

Patient Information leaflet

                                50
Б. ЛИСТОВКА
51
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПАЦИЕНТА
ADVAGRAF 0,5 MG ТВЪРДИ КАПСУЛИ С УДЪЛЖЕНО
ОСВОБОЖДАВАНЕ
ADVAGRAF 1 MG ТВЪРДИ КАПСУЛИ С УДЪЛЖЕНО
ОСВОБОЖДАВАНЕ
ADVAGRAF 3 MG ТВЪРДИ КАПСУЛИ С УДЪЛЖЕНО
ОСВОБОЖДАВАНЕ
ADVAGRAF 5 MG ТВЪРДИ КАПСУЛИ С УДЪЛЖЕНО
ОСВОБОЖДАВАНЕ
Такролимус (Tacrolimus)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар или
фармацевт. Това включва и всички
възможни нежелани реакции, неописани
в тази
листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА:
1.
Какво представлява Advagraf и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете Advagraf
3.
Как да приемате Advagraf
4.
Възможни нежелани реакции
5.
Как да съхранявате Advagraf
6.
Съдържание на опаковката и
д
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Advagraf 0,5 mg твърди капсули с удължено
освобождаване
Advagraf 1 mg твърди капсули с удължено
освобождаване
Advagraf 3 mg твърди капсули с удължено
освобождаване
Advagraf 5 mg твърди капсули с удължено
освобождаване
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Advagraf 0,5 mg твърди капсули с удължено
освобождаване
Всяка твърда капсула с удължено
освобождаване съдържа 0,5 mg такролимус
(tacrolimus) (като
монохидрат).
Помощни вещества с известно действие:
Всяка капсула съдържа 51,09 mg лактоза.
Печатното мастило, използвано за
маркиране на капсулата, съдържа следи
от соев
лецитин (0,48% от общото количество на
печатното мастило).
Advagraf 1 mg твърди капсули с удължено
освобождаване
Всяка твърда капсула с удължено
освобождаване съдържа 1 mg такролимус
(tacrolimus) (като
монохидрат).
Помощни вещества с известно действие:
Всяка капсула съдържа 102,17 mg лактоза.
Печатно мастило, използвано за
маркиране на капсулата, съдържа следи
от соев лецитин
(0,48% от общото количество на печатното
мастило).
Advagraf 3 mg твърди капсули с удължено
освобождаване
Всяка твърда капсула с удължено
освобождаване съдържа 3 
                                
                                Read the complete document

Similar products

Active ingredient такролимус

такролимус

ATC code L04AD02

L04AD02

Marketed by Astellas Pharma Europe BV

Astellas Pharma Europe BV

INN (International Name) tacrolimus

tacrolimus

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 30-10-2023
Summary of Product characteristics Summary of Product characteristics Spanish 30-10-2023
Public Assessment Report Public Assessment Report Spanish 31-03-2008
Patient Information leaflet Patient Information leaflet Czech 30-10-2023
Summary of Product characteristics Summary of Product characteristics Czech 30-10-2023
Public Assessment Report Public Assessment Report Czech 31-03-2008
Patient Information leaflet Patient Information leaflet Danish 30-10-2023
Summary of Product characteristics Summary of Product characteristics Danish 30-10-2023
Public Assessment Report Public Assessment Report Danish 31-03-2008
Patient Information leaflet Patient Information leaflet German 30-10-2023
Summary of Product characteristics Summary of Product characteristics German 30-10-2023
Public Assessment Report Public Assessment Report German 31-03-2008
Patient Information leaflet Patient Information leaflet Estonian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Estonian 30-10-2023
Public Assessment Report Public Assessment Report Estonian 31-03-2008
Patient Information leaflet Patient Information leaflet Greek 30-10-2023
Summary of Product characteristics Summary of Product characteristics Greek 30-10-2023
Public Assessment Report Public Assessment Report Greek 31-03-2008
Patient Information leaflet Patient Information leaflet English 30-10-2023
Summary of Product characteristics Summary of Product characteristics English 30-10-2023
Public Assessment Report Public Assessment Report English 31-03-2008
Patient Information leaflet Patient Information leaflet French 30-10-2023
Summary of Product characteristics Summary of Product characteristics French 30-10-2023
Public Assessment Report Public Assessment Report French 31-03-2008
Patient Information leaflet Patient Information leaflet Italian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Italian 30-10-2023
Public Assessment Report Public Assessment Report Italian 31-03-2008
Patient Information leaflet Patient Information leaflet Latvian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Latvian 30-10-2023
Public Assessment Report Public Assessment Report Latvian 31-03-2008
Patient Information leaflet Patient Information leaflet Lithuanian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-10-2023
Public Assessment Report Public Assessment Report Lithuanian 31-03-2008
Patient Information leaflet Patient Information leaflet Hungarian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-10-2023
Public Assessment Report Public Assessment Report Hungarian 31-03-2008
Patient Information leaflet Patient Information leaflet Maltese 30-10-2023
Summary of Product characteristics Summary of Product characteristics Maltese 30-10-2023
Public Assessment Report Public Assessment Report Maltese 31-03-2008
Patient Information leaflet Patient Information leaflet Dutch 30-10-2023
Summary of Product characteristics Summary of Product characteristics Dutch 30-10-2023
Public Assessment Report Public Assessment Report Dutch 31-03-2008
Patient Information leaflet Patient Information leaflet Polish 30-10-2023
Summary of Product characteristics Summary of Product characteristics Polish 30-10-2023
Public Assessment Report Public Assessment Report Polish 31-03-2008
Patient Information leaflet Patient Information leaflet Portuguese 30-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-10-2023
Public Assessment Report Public Assessment Report Portuguese 31-03-2008
Patient Information leaflet Patient Information leaflet Romanian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Romanian 30-10-2023
Public Assessment Report Public Assessment Report Romanian 31-03-2008
Patient Information leaflet Patient Information leaflet Slovak 30-10-2023
Summary of Product characteristics Summary of Product characteristics Slovak 30-10-2023
Public Assessment Report Public Assessment Report Slovak 31-03-2008
Patient Information leaflet Patient Information leaflet Slovenian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-10-2023
Public Assessment Report Public Assessment Report Slovenian 31-03-2008
Patient Information leaflet Patient Information leaflet Finnish 30-10-2023
Summary of Product characteristics Summary of Product characteristics Finnish 30-10-2023
Public Assessment Report Public Assessment Report Finnish 31-03-2008
Patient Information leaflet Patient Information leaflet Swedish 30-10-2023
Summary of Product characteristics Summary of Product characteristics Swedish 30-10-2023
Public Assessment Report Public Assessment Report Swedish 31-03-2008
Patient Information leaflet Patient Information leaflet Norwegian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-10-2023
Patient Information leaflet Patient Information leaflet Croatian 30-10-2023
Summary of Product characteristics Summary of Product characteristics Croatian 30-10-2023

Search alerts related to this product

Alerts Advagraf такролимус tacrolimus

Advagraf такролимус tacrolimus

View documents history

Documents history Documents history

Advagraf